Phase 3 Ganglioneuroblastoma Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled177 locationsNCT06172296
Recruiting
Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NeuroblastomaGanglioneuroblastoma, NodularGanglioneuroblastoma
Children's Oncology Group750 enrolled162 locationsNCT03126916
Recruiting
Phase 3
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Neuroblastoma (NB)Ganglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology5 enrolled1 locationNCT07375563
Recruiting
Phase 3
Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
NeuroblastomaGanglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology15 enrolled1 locationNCT06071897